The world of respiratory health is undergoing a significant shift, and it's not just about treating illnesses; it's about preventing them, especially when it comes to our most vulnerable population: infants and young children. The focus on respiratory syncytial virus (RSV) prevention has expanded beyond the first season, and now, the spotlight is on high-risk children entering their second RSV season. This shift in perspective is a game-changer, and it's about time we talk about it.
The RSV Challenge
RSV is a formidable opponent, infecting an astonishing 90% of children before their second birthday. Infants under six months are particularly at risk, with infections potentially leading to severe respiratory issues like bronchiolitis and pneumonia, often requiring hospitalization. The lack of a specific treatment underscores the critical importance of prevention.
A Global Market Awakening
The global market for RSV prevention is waking up, and it's doing so with a bang. Grand View Research estimates the market value at a whopping $28.39 billion by 2030, growing at an incredible 42.17% CAGR. This rapid expansion is a testament to the growing awareness and urgency surrounding RSV prevention.
Korea's Journey
Korea's experience with RSV prevention is an intriguing one. The introduction of preventive antibodies like Beyfortus and Enflonsia has sparked a conversation about the need for comprehensive prevention strategies. The decline in infant hospitalizations during the 2025-2026 RSV season, post-Beyfortus introduction, is a notable development, although more data is needed to establish a causal link.
The High-Risk Dilemma
High-risk children, those with chronic lung or heart disease or compromised immune systems, present a unique challenge. While Beyfortus offers protection for these children in their second RSV season, the previous standard, Synagis, required five monthly injections, a burden for patients and caregivers. The convenience and effectiveness of Beyfortus are a significant step forward, and its recommendation by the U.S. CDC is a strong endorsement.
A Call for Universal Prevention
Professor Choe Young-june's perspective is insightful. With RSV being the leading cause of lower respiratory tract infections in infants, prevention is not just important; it's critical. The inability to predict which infants will develop severe disease underscores the need for a two-pronged approach: universal prevention for the first season and additional management for high-risk children throughout their second season.
A Vision for the Future
Choe's vision of a future where all newborns, infants, and high-risk children are protected against RSV without financial barriers is inspiring. It's a call to action, a reminder that while we've made progress, there's still much work to be done. The journey towards universal RSV prevention is ongoing, and it's a journey we must all support and advocate for.
